DrugPatentWatch Database Preview

Details for Patent: 6,051,567

« Back to Dashboard

Which drugs does patent 6,051,567 protect, and when does it expire?

Patent 6,051,567 protects CALCIJEX and is included in one NDA.

Protection for CALCIJEX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 6,051,567

Title:	Low oxygen content compositions of 1.alpha., 25-dihydroxycholecalciferol
Abstract:	The invention relates to stable aqueous formulations comprising 1.alpha., 25-dihydroxycholecalciferol, a unit dose system comprising the same in a sealed vessel, and a process for preparing them.
Inventor(s):	Abrahamson; Kent (Libertyville, IL), Anderson; Amy N. (Waukegan, IL), Grady; Haiyan (Mundelein, IL)
Assignee:	Abbott Laboratories (Abbott Park, IL)
Application Number:	09/365,533
Patent Claim Types: see list of patent claims	Formulation; Compound; Composition;

Drugs Protected by US Patent 6,051,567

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Abbvie	CALCIJEX	calcitriol	INJECTABLE;INJECTION	018874-001	Sep 25, 1986		DISCN	Yes	No					Y
Abbvie	CALCIJEX	calcitriol	INJECTABLE;INJECTION	018874-002	Sep 25, 1986		DISCN	Yes	No					Y

Non-Orange Book US Patents Family Members for Patent 6,051,567

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
6,265,392	Low oxygen content compositions of 1.alpha., 25-dihydroxycholeclciferol